Ignite Creation Date:
2025-12-25 @ 1:07 AM
Ignite Modification Date:
2026-01-02 @ 2:56 AM
Study NCT ID:
NCT04223193
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2020-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Flexible-Dose Trial in Early Parkinson's Disease (PD)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-10-08', 'type': 'ESTIMATED'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}, {'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}], 'ancestors': [{'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'abbvieclinicaltrials@abbvie.com', 'phone': '800-633-9110', 'title': 'Global Medical Services', 'organization': 'AbbVie'}, 'certainAgreement': {'otherDetails': 'AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'All-cause mortality were reported from enrollment until 4 weeks after the end of study. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug. Mean duration on study drug was 176.7 and 144.5 days for Placebo and Tavapadon, respectively. Median time on follow up (median time subjects were followed) was 200 and 198 days for Placebo and Tavapadon, respectively.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.', 'otherNumAtRisk': 153, 'deathsNumAtRisk': 153, 'otherNumAffected': 59, 'seriousNumAtRisk': 153, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.', 'otherNumAtRisk': 151, 'deathsNumAtRisk': 151, 'otherNumAffected': 99, 'seriousNumAtRisk': 151, 'deathsNumAffected': 0, 'seriousNumAffected': 7}], 'otherEvents': [{'term': 'CONSTIPATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DIARRHOEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DRY MOUTH', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DYSPEPSIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'GASTROOESOPHAGEAL REFLUX DISEASE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'NAUSEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 54, 'numAffected': 45}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'SALIVARY HYPERSECRETION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'VOMITING', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 14, 'numAffected': 12}], 'organSystem': 'GASTROINTESTINAL DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'ASTHENIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'FATIGUE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 14, 'numAffected': 12}], 'organSystem': 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'BRONCHITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'INFECTIONS AND INFESTATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'INFECTIONS AND INFESTATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'UPPER RESPIRATORY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'INFECTIONS AND INFESTATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'URINARY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'INFECTIONS AND INFESTATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 10, 'numAffected': 8}], 'organSystem': 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DECREASED APPETITE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'METABOLISM AND NUTRITION DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'ARTHRALGIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'BACK PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'PAIN IN EXTREMITY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DIZZINESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 7, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 28, 'numAffected': 24}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DYSGEUSIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 12, 'numAffected': 12}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'HEADACHE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 11, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 37, 'numAffected': 25}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'PARAESTHESIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': "PARKINSON'S DISEASE", 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'SOMNOLENCE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'TREMOR', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 15, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'ABNORMAL DREAMS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'PSYCHIATRIC DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'ANXIETY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'PSYCHIATRIC DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'INSOMNIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'PSYCHIATRIC DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'HYPOTENSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'VASCULAR DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}], 'seriousEvents': [{'term': 'HYPERCHROMIC ANAEMIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'BLOOD AND LYMPHATIC SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'FEMORAL NECK FRACTURE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'HEAD INJURY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'JOINT INJURY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'PRESYNCOPE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'NERVOUS SYSTEM DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'DEPRESSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'PSYCHIATRIC DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'HYPERHIDROSIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}, {'term': 'HYPERTENSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 153, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 151, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'VASCULAR DISORDERS', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 27.1'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': "Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score", 'denoms': [{'units': 'Participants', 'counts': [{'value': '133', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '-10.3', 'spread': '0.99', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.1', 'ciLowerLimit': '-11.7', 'ciUpperLimit': '-6.5', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.31', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 26', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline MDS-UPDRS assessment, and had available data for analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the MDS-UPDRS Part II Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '0.33', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.0007', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.5', 'ciLowerLimit': '-2.4', 'ciUpperLimit': '-0.6', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.44', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 26', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline MDS-UPDRS assessment, and had available data for analysis.'}, {'type': 'SECONDARY', 'title': 'Percentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '25', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.942', 'ciLowerLimit': '2.209', 'ciUpperLimit': '7.037', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 26', 'description': 'The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed.\n\nScores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline PGIC assessment, and had available data for analysis.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the MDS-UPDRS Parts II and III Combined Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '-5.5', 'spread': '0.63', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '119', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '-8.5', 'spread': '0.69', 'groupId': 'OG001'}]}]}, {'title': 'Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '0.71', 'groupId': 'OG000'}, {'value': '-9.5', 'spread': '0.77', 'groupId': 'OG001'}]}]}, {'title': 'Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '0.76', 'groupId': 'OG000'}, {'value': '-10.3', 'spread': '0.84', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '0.85', 'groupId': 'OG000'}, {'value': '-10.0', 'spread': '0.93', 'groupId': 'OG001'}]}]}, {'title': 'Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '-10.1', 'spread': '0.92', 'groupId': 'OG001'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '133', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '-10.3', 'spread': '0.99', 'groupId': 'OG001'}]}]}, {'title': 'Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.89', 'groupId': 'OG000'}, {'value': '-10.4', 'spread': '0.99', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.1', 'ciLowerLimit': '-11.7', 'ciUpperLimit': '-6.5', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.31', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '-5.2', 'spread': '0.72', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '119', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '-8.3', 'spread': '0.79', 'groupId': 'OG001'}]}]}, {'title': 'Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '-9.3', 'spread': '0.89', 'groupId': 'OG001'}]}]}, {'title': 'Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '-10.4', 'spread': '0.96', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '-10.1', 'spread': '1.05', 'groupId': 'OG001'}]}]}, {'title': 'Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '-10.1', 'spread': '1.07', 'groupId': 'OG001'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '133', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '-9.9', 'spread': '1.15', 'groupId': 'OG001'}]}]}, {'title': 'Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '-10.2', 'spread': '1.14', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.3', 'ciLowerLimit': '-11.3', 'ciUpperLimit': '-5.3', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.52', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Part I: Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '0.25', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '146', 'groupId': 'OG000'}, {'value': '120', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '0.25', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '0.27', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '0.25', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '0.27', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '0.25', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.27', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '0.25', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.27', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.27', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '0.30', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '0.32', 'groupId': 'OG001'}]}]}, {'title': 'Part I: Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '0.28', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '0.31', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '-1.0', 'spread': '0.24', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '146', 'groupId': 'OG000'}, {'value': '120', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '0.25', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.26', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '0.28', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.26', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '0.29', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.27', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '0.30', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '0.32', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '0.33', 'groupId': 'OG001'}]}]}, {'title': 'Part II: Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '0.34', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '-4.5', 'spread': '0.52', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '119', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '0.53', 'groupId': 'OG000'}, {'value': '-7.0', 'spread': '0.58', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '0.58', 'groupId': 'OG000'}, {'value': '-8.1', 'spread': '0.64', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '0.63', 'groupId': 'OG000'}, {'value': '-8.6', 'spread': '0.69', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '-8.4', 'spread': '0.77', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '0.68', 'groupId': 'OG000'}, {'value': '-8.7', 'spread': '0.76', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '133', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.71', 'groupId': 'OG000'}, {'value': '-8.9', 'spread': '0.80', 'groupId': 'OG001'}]}]}, {'title': 'Part III: Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.71', 'groupId': 'OG000'}, {'value': '-9.0', 'spread': '0.80', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.0766', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.7', 'ciLowerLimit': '-0.1', 'ciUpperLimit': '1.6', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.42', 'groupDescription': 'Part I: Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.0007', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.5', 'ciLowerLimit': '-2.4', 'ciUpperLimit': '-0.6', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.44', 'groupDescription': 'Part II: Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-7.6', 'ciLowerLimit': '-9.7', 'ciUpperLimit': '-5.6', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.05', 'groupDescription': 'Part III: Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '147', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.05', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '119', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.05', 'groupId': 'OG001'}]}]}, {'title': 'Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.06', 'groupId': 'OG001'}]}]}, {'title': 'Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.05', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.06', 'groupId': 'OG001'}]}]}, {'title': 'Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '0.06', 'groupId': 'OG001'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '0.06', 'groupId': 'OG001'}]}]}, {'title': 'Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.06', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.4', 'ciLowerLimit': '-0.5', 'ciUpperLimit': '-0.2', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.08', 'groupDescription': 'Wek 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants).\n\nHigher values represent a worse outcome.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Clinical Global Impression - Improvement (CGI-I) Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '0.07', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '146', 'groupId': 'OG000'}, {'value': '120', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '0.07', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '0.08', 'groupId': 'OG001'}]}]}, {'title': 'Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '3.0', 'spread': '0.09', 'groupId': 'OG001'}]}]}, {'title': 'Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '0.09', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '0.10', 'groupId': 'OG001'}]}]}, {'title': 'Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '0.10', 'groupId': 'OG001'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '2.7', 'spread': '0.11', 'groupId': 'OG001'}]}]}, {'title': 'Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '0.11', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.0', 'ciLowerLimit': '-1.3', 'ciUpperLimit': '-0.7', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the PGIC Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}, {'value': '150', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Week 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '127', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '3.3', 'spread': '0.09', 'groupId': 'OG001'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '120', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '0.09', 'groupId': 'OG001'}]}]}, {'title': 'Week 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '140', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '0.10', 'groupId': 'OG001'}]}]}, {'title': 'Week 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '0.11', 'groupId': 'OG001'}]}]}, {'title': 'Week 18', 'denoms': [{'units': 'Participants', 'counts': [{'value': '138', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '0.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '137', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '0.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '0.12', 'groupId': 'OG001'}]}]}, {'title': 'Week 27', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '100', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.8', 'spread': '0.11', 'groupId': 'OG000'}, {'value': '2.8', 'spread': '0.12', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.0', 'ciLowerLimit': '-1.3', 'ciUpperLimit': '-0.7', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': 'The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed.\n\nScores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT Population'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Epworth Sleepiness Scale (ESS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '98', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '0.24', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.9795', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0', 'ciLowerLimit': '-0.6', 'ciUpperLimit': '0.6', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.32', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 26', 'description': 'The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome. A negative change from baseline represents an improvement in daytime sleepiness. The total ESS score range was 0 - 24.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS population includes all randomized participants who received at least 1 dose of study drug, and had available data for analysis.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)", 'denoms': [{'units': 'Participants', 'counts': [{'value': '134', 'groupId': 'OG000'}, {'value': '99', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.9', 'spread': '0.31', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '0.34', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.8916', 'groupIds': ['OG000', 'OG001'], 'paramType': 'LS Mean of Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.1', 'ciLowerLimit': '-0.9', 'ciUpperLimit': '0.8', 'pValueComment': "LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.", 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.45', 'groupDescription': 'Week 26', 'statisticalMethod': 'Mixed-effect Model Repeated Measurement', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Week 26', 'description': 'QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson\'s disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/ desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \\[0 means "never" and 4 means "very often"\\] for each question) to gauge the frequency of behaviors.\n\nScores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms. A negative change from baseline represents an improvement in ICDs.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS population includes all randomized participants who received at least 1 dose of study drug, and had available data for analysis.'}, {'type': 'SECONDARY', 'title': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '151', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Participants With Any Suicidal Ideations', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Participants With Any Suicidal Behaviors', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Participants With Any Suicidal Behaviors or Ideations', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Participants With Non-Suicidal Self-Injurious Behavior', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Week 27', 'description': 'The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS population'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'OG000'}, {'value': '151', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'OG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '84', 'groupId': 'OG000'}, {'value': '115', 'groupId': 'OG001'}]}]}, {'title': 'TESAE', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study drug until 190 days following last dose of study drug.', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS Population'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'FG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '153'}, {'groupId': 'FG001', 'numSubjects': '151'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '130'}, {'groupId': 'FG001', 'numSubjects': '94'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '23'}, {'groupId': 'FG001', 'numSubjects': '57'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '36'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Failure to Meet Continuation Criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Treatment with Prohibited Concomitant Medications', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Non-Compliance with Study Drug', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Site Terminated by Sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '6'}]}]}], 'preAssignmentDetails': "In this Phase 3, Double-Blind study, a total of 304 participants with Parkinson's Disease (PD) were randomized in a 1:1 ratio to either Placebo, or tavapadon 5 mg to 15 mg once daily (QD) for 27 Weeks."}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '153', 'groupId': 'BG000'}, {'value': '151', 'groupId': 'BG001'}, {'value': '304', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Participants received placebo matching to Tavapadon tablet once daily (QD) orally for 27 weeks.'}, {'id': 'BG001', 'title': 'Tavapadon', 'description': 'Participants received Tavapadon 5 mg to 15 mg tablet QD orally for 27 weeks.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '62.6', 'spread': '9.43', 'groupId': 'BG000'}, {'value': '63.1', 'spread': '8.98', 'groupId': 'BG001'}, {'value': '62.9', 'spread': '9.20', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '68', 'groupId': 'BG000'}, {'value': '67', 'groupId': 'BG001'}, {'value': '135', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '85', 'groupId': 'BG000'}, {'value': '84', 'groupId': 'BG001'}, {'value': '169', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '137', 'groupId': 'BG000'}, {'value': '141', 'groupId': 'BG001'}, {'value': '278', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '134', 'groupId': 'BG000'}, {'value': '134', 'groupId': 'BG001'}, {'value': '268', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'MDS-UPDRS Score at Baseline (Parts II and III Combined)', 'classes': [{'categories': [{'measurements': [{'value': '30.0', 'spread': '11.11', 'groupId': 'BG000'}, {'value': '31.1', 'spread': '11.21', 'groupId': 'BG001'}, {'value': '30.5', 'spread': '11.16', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': "The MDS-UPDRS rating tool was used to follow longitudinal course of Parkinson's Disease and consisted of 4 parts.Part 1:Non-motor aspects of experiences of daily living\\[13 items,Score range(SR):0-52\\];Part 2:Motor aspects of experiences of daily living(13 items,SR:0-52);Part 3:Motor examination(18 items,SR:0-132);Part 4:Motor complications(6 items,SR:0-24.Not collected).Each item has 0-4 rating on scale from 0(normal)-4(severe).Higher values represent a worse outcome.Parts 2 and 3 combined is the sum of Part 2 and Part 3 scores at each assessment time for each participant(31 items,SR:0-184).", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION'}], 'populationDescription': 'ITT Population includes all randomized participants.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-07-06', 'size': 3453595, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2025-09-19T12:22', 'hasProtocol': True}, {'date': '2024-10-23', 'size': 5664047, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2025-09-19T12:24', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 304}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-01-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2024-10-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-07', 'studyFirstSubmitDate': '2020-01-07', 'resultsFirstSubmitDate': '2025-09-19', 'studyFirstSubmitQcDate': '2020-01-07', 'lastUpdatePostDateStruct': {'date': '2025-11-21', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2025-11-07', 'studyFirstPostDateStruct': {'date': '2020-01-10', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-11-21', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2024-10-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score", 'timeFrame': 'Week 26', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184."}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in the MDS-UPDRS Part II Score', 'timeFrame': 'Week 26', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function."}, {'measure': 'Percentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)', 'timeFrame': 'Week 26', 'description': 'The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed.\n\nScores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.'}, {'measure': 'Change From Baseline in the MDS-UPDRS Parts II and III Combined Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184."}, {'measure': 'Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236."}, {'measure': 'Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function."}, {'measure': 'Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants).\n\nHigher values represent a worse outcome."}, {'measure': 'Clinical Global Impression - Improvement (CGI-I) Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': "The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome."}, {'measure': 'Change From Baseline in the PGIC Score', 'timeFrame': 'Week 5, 8, 11, 14, 18, 22, 26, and 27', 'description': 'The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed.\n\nScores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.'}, {'measure': 'Change From Baseline in the Epworth Sleepiness Scale (ESS)', 'timeFrame': 'Week 26', 'description': 'The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome. A negative change from baseline represents an improvement in daytime sleepiness. The total ESS score range was 0 - 24.'}, {'measure': "Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)", 'timeFrame': 'Week 26', 'description': 'QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson\'s disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/ desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \\[0 means "never" and 4 means "very often"\\] for each question) to gauge the frequency of behaviors.\n\nScores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms. A negative change from baseline represents an improvement in ICDs.'}, {'measure': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'timeFrame': 'Week 27', 'description': 'The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'From first dose of study drug until 190 days following last dose of study drug.', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Parkinsonian Disorders', 'Brain Diseases', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Movement Disorders', 'Neurodegenerative Diseases'], 'conditions': ['Parkinson Disease']}, 'descriptionModule': {'briefSummary': "The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria:\n\n* Male and female participants aged 40 to 80 years, inclusive, at the time of signing the informed consent form (ICF).\n* Sexually active men or women of childbearing potential must agree to use acceptable (at minimum) or highly effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.\n* Participants who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.\n* Participants with a diagnosis of PD that is consistent with the UK Parkinson\'s Disease Society Brain Bank diagnostic criteria.\n* Participants with modified Hoehn and Yahr stage 1, 1.5, or 2.\n* Participants with disease duration (from time of diagnosis) of less than (\\<) 3 years and disease progression in the 3 years before signing the ICF.\n* Participants with an MDS-UPDRS Part II score \\>=2 and Part III score \\>=10 at the Screening Visit and at the Baseline Visit.\n* Participants with early PD who, in the opinion of the investigator, require pharmacologic intervention for disease management.\n* Participants who are treatment naive or have a history of prior incidental treatment with dopaminergic agents (including L-Dopa and dopamine receptor agonist medications) for \\<3 months in total but not within 2 months of the Baseline Visit. Prior and concurrent use of MAO-B inhibitors is permitted if use was initiated \\>90 days before the Baseline Visit and the dosage will remain stable for the duration of the trial (ie, no change in the MAO-B inhibitor dose is permitted during the trial).\n* Participants who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.\n\nKey Exclusion Criteria:\n\n* Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supra nuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or post stroke parkinsonism).\n* Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.\n* Participants with a history or current diagnosis of a clinically significant impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM-5).\n* Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures.\n* Participants with a history of psychosis or hallucinations within the previous 12 months.\n* Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.\n* Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days).\n* Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the participant from understanding the ICF or participating in the trial.\n* Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).\n* Participants who have a positive result for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibodies at screening.\n* Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12 months. A recent (less than or equal to \\[\\<=\\] 12 months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.\n* Participants with a history of neuroleptic malignant syndrome.\n* Participants who are currently receiving moderate or strong CYP3A4 inducers or CYP3A4 inhibitors (except for topical administration).\n* Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any Tetrahydrocannabinol \\[THC\\]-containing product), prescription, or over-the-counter medications or products that, in the investigator\'s documented opinion, do not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor.\n* Participants with a Montreal Cognitive Assessment (MoCA) score \\<26.\n* Participants with clinically significant orthostatic hypotension (eg, syncope).\n* Participants with a 12-lead ECG demonstrating a QTcF interval \\>450 msec.\n* Participants with moderate or severe renal impairment (creatinine clearance as estimated by Cockcroft-Gault formula \\<30 mL/min or on dialysis).\n* Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary:\n\n * Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \\>=3 × Upper Limit Normal (ULN).\n * Total bilirubin \\>=1.5 × ULN. Participants with a history of Gilbert\'s syndrome may be eligible provided they have a value \\<ULN for direct bilirubin.\n* Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the participants or the interpretation of the trial results.'}, 'identificationModule': {'nctId': 'NCT04223193', 'acronym': 'TEMPO-2', 'briefTitle': "Flexible-Dose Trial in Early Parkinson's Disease (PD)", 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': "A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)", 'orgStudyIdInfo': {'id': 'CVL-751-PD-002'}, 'secondaryIdInfos': [{'id': '2019-002950-22', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Tavapadon', 'description': 'Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.', 'interventionNames': ['Drug: Tavapadon']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Tavapadon', 'type': 'DRUG', 'otherNames': ['PF-06649751', 'CVL-751'], 'description': 'Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.', 'armGroupLabels': ['Tavapadon']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive placebo matching to tavapadon QD orally for 27 weeks.', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93710', 'city': 'Fresno', 'state': 'California', 'country': 'United States', 'facility': 'Fresno, California', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'zip': '33487', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': 'Boca Raton, Florida', 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '32751', 'city': 'Maitland', 'state': 'Florida', 'country': 'United States', 'facility': 'Maitland, Florida', 'geoPoint': {'lat': 28.62778, 'lon': -81.36312}}, {'zip': '34470', 'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': 'Ocala, Florida', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'zip': '32792', 'city': 'Winter Park', 'state': 'Florida', 'country': 'United States', 'facility': 'Winter Park, Florida', 'geoPoint': {'lat': 28.6, 'lon': -81.33924}}, {'zip': '02747', 'city': 'North Dartmouth', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Boston Neuro Research Center', 'geoPoint': {'lat': 41.63899, 'lon': -70.97032}}, {'zip': '12208', 'city': 'Albany', 'state': 'New York', 'country': 'United States', 'facility': 'Albany, New York', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'Syracuse, New York', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '45212', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cincinnati, Ohio', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland, Ohio', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '38157', 'city': 'Memphis', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Memphis, Tennessee', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '77429', 'city': 'Cypress', 'state': 'Texas', 'country': 'United States', 'facility': 'Cypress, Texas', 'geoPoint': {'lat': 29.96911, 'lon': -95.69717}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston, Texas', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '79410', 'city': 'Lubbock', 'state': 'Texas', 'country': 'United States', 'facility': 'Lubbock, Texas', 'geoPoint': {'lat': 33.57786, 'lon': -101.85517}}, {'zip': '78681', 'city': 'Round Rock', 'state': 'Texas', 'country': 'United States', 'facility': 'Round Rock, Texas', 'geoPoint': {'lat': 30.50826, 'lon': -97.6789}}, {'zip': '23229', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'Richmond, Virginia', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '23233', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'Richmond, Virginia', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '98034', 'city': 'Kirkland', 'state': 'Washington', 'country': 'United States', 'facility': 'Kirkland, Washington', 'geoPoint': {'lat': 47.68149, 'lon': -122.20874}}, {'zip': '2109', 'city': 'Sydney', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Macquarie Park, New South Wales', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '13385', 'city': 'Marseille', 'state': 'France', 'country': 'France', 'facility': 'Marseille, France', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '44093', 'city': 'Nantes', 'state': 'Nantes', 'country': 'France', 'facility': 'Nantes CEDEX 1', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '31059', 'city': 'Toulouse', 'state': 'Toulouse', 'country': 'France', 'facility': 'Toulouse Cedex 9', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '44791', 'city': 'Bochum', 'state': 'Bochum', 'country': 'Germany', 'facility': 'Bochum', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'zip': '07551', 'city': 'Gera', 'state': 'Gera', 'country': 'Germany', 'facility': 'Gera', 'geoPoint': {'lat': 50.88029, 'lon': 12.08187}}, {'zip': '81377', 'city': 'München', 'state': 'Muenchen', 'country': 'Germany', 'facility': 'Muenchen', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '12163', 'city': 'Berlin', 'state': 'State of Berlin', 'country': 'Germany', 'facility': 'Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '1135', 'city': 'Budapest', 'state': 'Budapest', 'country': 'Hungary', 'facility': 'Budapest', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '7623', 'city': 'Pécs', 'state': 'Hungary', 'country': 'Hungary', 'facility': 'Pecs', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '2800', 'city': 'Tatabánya', 'country': 'Hungary', 'facility': 'Tatabanya', 'geoPoint': {'lat': 47.59247, 'lon': 18.38099}}, {'zip': '03043', 'city': 'Cassino', 'state': 'Cassino', 'country': 'Italy', 'facility': 'Cassino', 'geoPoint': {'lat': 41.48581, 'lon': 13.82835}}, {'zip': '20132', 'city': 'Milan', 'state': 'Milano', 'country': 'Italy', 'facility': 'Milano', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '00133', 'city': 'Rome', 'state': 'Rome', 'country': 'Italy', 'facility': 'Rome', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '20089', 'city': 'Rozzano', 'country': 'Italy', 'facility': 'Rozzano Milano', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '10126', 'city': 'Torino', 'country': 'Italy', 'facility': 'Torino', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'zip': '31-505', 'city': 'Krakow', 'state': 'Cracow', 'country': 'Poland', 'facility': 'Cracow', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '40-097', 'city': 'Katowice', 'state': 'Katowice', 'country': 'Poland', 'facility': 'Katowice', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '41-100', 'city': 'Siemianowice Śląskie', 'state': 'Siemianowice Slaskie', 'country': 'Poland', 'facility': 'Siemianowice Slaskie', 'geoPoint': {'lat': 50.32738, 'lon': 19.02901}}, {'zip': '85-163', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Centrum Medyczne NEUROMED', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '20-701', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Centrum Medyczne Hope Clinic Sebastian Szklener', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '11000', 'city': 'Belgrade', 'state': 'Belgrade', 'country': 'Serbia', 'facility': 'Belgrade', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '02447', 'city': 'Seoul', 'state': 'Dongdaemun-gu', 'country': 'South Korea', 'facility': 'Dongdaemun-gu, Seoul', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '48108', 'city': 'Busan', 'state': 'Haeundae-gu', 'country': 'South Korea', 'facility': 'Haeundae-gu, Busan', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'zip': '05505', 'city': 'Seoul', 'state': 'Songpa-gu', 'country': 'South Korea', 'facility': 'Songpa-gu, Seoul', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08035', 'city': 'Barcelona', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28938', 'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Móstoles, Madrid', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '100225', 'city': 'Zhongzheng', 'state': 'Taipei', 'country': 'Taiwan', 'facility': 'Zhongzheng, Taipei'}, {'zip': '112062', 'city': 'Zhongzheng', 'state': 'Taipei', 'country': 'Taiwan', 'facility': 'Zhongzheng, Taipei'}, {'zip': '10400', 'city': 'Ratchathewi', 'state': 'Bangkok', 'country': 'Thailand', 'facility': 'Ratchathewi, Bangkok', 'geoPoint': {'lat': 13.759, 'lon': 100.53358}}, {'zip': '12120', 'city': 'Khlong Luang', 'state': 'Changwat Pathum Thani', 'country': 'Thailand', 'facility': 'Khlong Luang, Pathum Thani', 'geoPoint': {'lat': 14.06467, 'lon': 100.64578}}, {'zip': '34000', 'city': 'Nai Muang', 'state': 'Changwat Ubon Ratchathani', 'country': 'Thailand', 'facility': 'Nai Muang, Ubon Ratchathani'}, {'zip': '04114', 'city': 'Kiev', 'state': 'Kyiv City', 'country': 'Ukraine', 'facility': 'Kiev', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '79010', 'city': 'Lviv', 'state': 'Lviv Oblast', 'country': 'Ukraine', 'facility': 'Lviv', 'geoPoint': {'lat': 49.83826, 'lon': 24.02324}}, {'zip': '21050', 'city': 'Vinnitsa', 'state': 'Vinnitsa', 'country': 'Ukraine', 'facility': 'Vinnitsa', 'geoPoint': {'lat': 49.84639, 'lon': 37.71861}}], 'overallOfficials': [{'name': 'ABBVIE Inc.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}